Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
NRX Pharmaceuticals Inc (NRXP)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: NRXP (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
3 Analysts rated it
Limited analyst coverage, niche firm, research info may be scarce.
1 Year Target Price $31.67
1 Year Target Price $31.67
| 3 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit 2.82% | Avg. Invested days 29 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 66.70M USD | Price to earnings Ratio - | 1Y Target Price 31.67 |
Price to earnings Ratio - | 1Y Target Price 31.67 | ||
Volume (30-day avg) 3 | Beta 1.55 | 52 Weeks Range 1.10 - 6.01 | Updated Date 06/30/2025 |
52 Weeks Range 1.10 - 6.01 | Updated Date 06/30/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.96 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) -191.74% | Return on Equity (TTM) -682.61% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 69550672 | Price to Sales(TTM) - |
Enterprise Value 69550672 | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA -0.15 | Shares Outstanding 19503400 | Shares Floating 13364027 |
Shares Outstanding 19503400 | Shares Floating 13364027 | ||
Percent Insiders 15.88 | Percent Institutions 13.08 |
Analyst Ratings
Rating 2 | Target Price 31.67 | Buy - | Strong Buy 3 |
Buy - | Strong Buy 3 | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
NRX Pharmaceuticals Inc
Company Overview
History and Background
NRX Pharmaceuticals, Inc. is a biopharmaceutical company founded in 2015, focused on developing novel therapeutics for the treatment of central nervous system disorders, specifically those underserved by existing treatments. It emerged from Relief Therapeutics Holding SA and has focused on bringing innovative therapies to patients with life-threatening conditions.
Core Business Areas
- Neuropsychiatry: Focuses on developing therapies for conditions like suicidal depression (NRX-101) and chronic pain. The primary focus is on conditions not adequately treated by current methods.
- Critical Care: Development of ZYESAMIu00ae (aviptadil) for respiratory distress and other critical care applications, particularly focusing on those related to COVID-19. They are exploring other applications beyond COVID-19
Leadership and Structure
The company has a management team led by Jonathan Javitt, MD, MPH, as Chairman and CEO. Their organizational structure includes clinical development, regulatory affairs, and commercial operations teams.
Top Products and Market Share
Key Offerings
- NRX-101: An investigational, oral, fixed-dose combination of D-cycloserine and lurasidone being developed for the treatment of Suicidal Treatment-Resistant Bipolar Depression (STR-BD). There is no market share since it's in clinical trials. Competitors: Janssen (Spravato), Allergan (Vraylar).
- ZYESAMIu00ae (aviptadil): A synthetic form of human Vasoactive Intestinal Polypeptide (VIP) under investigation for respiratory distress, including ARDS related to COVID-19. It has received Fast Track Designation. There is no market share since it is still in clinical trials. Competitors: Gilead (Remdesivir), Roche (Actemra).
Market Dynamics
Industry Overview
The pharmaceutical industry is highly competitive, with significant investment in R&D. It involves developing, manufacturing, and marketing drugs. Novel therapeutics are in high demand, especially for unmet medical needs.
Positioning
NRX Pharmaceuticals positions itself as an innovator focused on addressing unmet needs in neuropsychiatry and critical care. Competitive advantages are driven by novel therapeutic approaches and regulatory designations.
Total Addressable Market (TAM)
The TAM for neuropsychiatric and critical care drugs is estimated to be in the billions of dollars annually. NRX Pharmaceuticals targets niche segments within these markets where current treatments are lacking.
Upturn SWOT Analysis
Strengths
- Novel therapeutic candidates
- Focus on unmet medical needs
- Experienced leadership team
- Fast Track Designation (ZYESAMIu00ae)
- Collaboration with Relief Therapeutics
Weaknesses
- Reliance on clinical trial success
- Limited commercialization experience
- High cash burn rate
- Dilution risk (frequent stock offerings)
- Dependence on key partnerships
Opportunities
- Positive clinical trial results
- Regulatory approvals
- Partnerships with larger pharmaceutical companies
- Expansion into new indications
- Government funding and grants
Threats
- Clinical trial failures
- Regulatory setbacks
- Competition from established players
- Patent challenges
- Economic downturn affecting healthcare spending
Competitors and Market Share
Key Competitors
- JNJ
- ABBV
- GILD
- RHHBY
Competitive Landscape
NRX Pharmaceuticals competes with larger, established pharmaceutical companies. Its competitive advantage lies in its novel therapies, but it faces challenges in terms of resources and market access. These percentages are not accurate and is only for demonstration.
Growth Trajectory and Initiatives
Historical Growth: Historical growth is primarily characterized by R&D activities and clinical trial advancements rather than revenue generation.
Future Projections: Future growth is dependent on clinical trial successes and regulatory approvals. Analyst estimates vary widely.
Recent Initiatives: Focus on advancing clinical trials for NRX-101 and ZYESAMIu00ae, seeking partnerships for commercialization.
Summary
NRX Pharmaceuticals is a high-risk, high-reward biopharmaceutical company focused on unmet medical needs. Its success hinges on positive clinical trial outcomes and regulatory approvals. Financial stability is a concern due to its high cash burn rate and reliance on funding. The company must effectively manage its clinical trials and partnerships to realize its potential.
Peer Comparison
Sources and Disclaimers
Data Sources:
- NRX Pharmaceuticals Investor Relations
- SEC Filings
- Company Press Releases
- Analyst Reports (where available)
Disclaimers:
The information provided is for informational purposes only and does not constitute investment advice. Investment decisions should be based on individual due diligence and consultation with a financial advisor. The data provided may not be entirely up-to-date and is subject to change.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About NRX Pharmaceuticals Inc
Exchange NASDAQ | Headquaters Wilmington, DE, United States | ||
IPO Launch date 2017-12-04 | Co-Founder, Chief Scientist Officer, Chairman & Interim CEO Dr. Jonathan C. Javitt M.D., M.P.H. | ||
Sector Healthcare | Industry Biotechnology | Full time employees - | Website https://www.nrxpharma.com |
Full time employees - | Website https://www.nrxpharma.com | ||
NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders comprising suicidal depression, post-traumatic stress disorder, and chronic pain. Its lead drug candidates include NRX-101, an oral, fixed dosed combination of D-cycloserine and lurasidone for suicidal treatment-resistant bipolar depression in patients with sub-acute suicidal ideation and behavior in phase 2 trial; and NRX-100, a preservative-free formulation of ketamine for intravenous infusion and for the treatment of suicidal depression. The company has a license agreement with Alvogen, Inc. and Lotus Pharmaceutical Co. Ltd.; Apkarian Technologies; development and license agreement with Glytech, LLC; and Sarah Herzog Memorial Hospital. NRx Pharmaceuticals, Inc. was founded in 2015 and is based in Wilmington, Delaware.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.